Two Small Treatments, a Lifetime of Protection: Why Newborns Need Vitamin K and Erythromycin
Understanding two important medications your baby receives shortly after birth.
Brett Mendez, DNP, APRN, NNP-BC | October 18, 2026
Welcoming a new baby into the world is an exciting and sometimes overwhelming experience. In the first hours after delivery, parents are introduced to a variety of newborn screenings, procedures, and medications. Among these are two routine preventive treatments: a vitamin K injection and erythromycin eye ointment.
While these medications have been used for decades, some parents understandably wonder whether they are truly necessary, particularly when their newborn appears perfectly healthy.
At VitalStart Pediatrics, we believe informed parents make empowered decisions. Understanding why these treatments are recommended can help families feel confident about protecting their newborns from preventable complications.
Vitamin K: Preventing Dangerous Bleeding
Why do newborns need vitamin K?
Vitamin K is an essential nutrient that helps the body produce proteins necessary for normal blood clotting. Without sufficient vitamin K, even minor bleeding can become dangerous.
Unlike older children and adults, newborns naturally have very low vitamin K stores. This happens for several reasons:
Vitamin K crosses the placenta poorly during pregnancy.
Newborn intestines have not yet developed the bacteria that contribute to vitamin K production.
Breast milk naturally contains relatively small amounts of vitamin K.
As a result, all newborns are at risk for vitamin K deficiency bleeding (VKDB), regardless of whether they are born at term, appear healthy, or have an uncomplicated delivery.
What is vitamin K deficiency bleeding?
VKDB is a potentially life-threatening condition in which a newborn develops abnormal bleeding because their body cannot clot blood effectively.
Bleeding may occur in the intestines, skin, or other organs. Most concerning, bleeding can occur inside the brain, potentially resulting in permanent neurological injury or death.
VKDB is classified into three categories:
Early VKDB: Occurs within the first 24 hours of life, often associated with certain maternal medications.
Classic VKDB: Typically develops between days 2 and 7 of life.
Late VKDB: Usually occurs between 2 and 8 weeks of age but may develop as late as 6 months.
Late VKDB is particularly concerning because it can occur unexpectedly in an otherwise healthy infant. In approximately 30%–60% of infants with late VKDB, bleeding occurs inside the skull.
How effective is the vitamin K injection?
A single intramuscular vitamin K injection shortly after birth provides highly effective protection against VKDB.
According to the Centers for Disease Control and Prevention (CDC), infants who do not receive the vitamin K injection are approximately 81 times more likely to develop late VKDB than infants who receive it.
The injection provides protection during the first months of life, while a baby's vitamin K availability and clotting system mature.
Can oral vitamin K replace the injection?
Although oral vitamin K is used in some countries under specific dosing protocols, it is not considered an equivalent alternative to the intramuscular injection in the United States.
Oral regimens require multiple doses, and protection may be less reliable, particularly in infants with unrecognized liver disease or problems absorbing fat-soluble vitamins.
For these reasons, the American Academy of Pediatrics (AAP) recommends intramuscular vitamin K for newborns.
A single injection shortly after birth can prevent a rare but potentially devastating bleeding disorder.
Erythromycin Eye Ointment: Protecting Your Baby's Vision
Why do newborns receive antibiotic eye ointment?
Shortly after birth, newborns are typically given erythromycin 0.5% ophthalmic ointment in both eyes.
Unlike vitamin K, which prevents a bleeding disorder, erythromycin helps prevent a serious eye infection known as gonococcal ophthalmia neonatorum.
This infection is caused by Neisseria gonorrhoeae, the bacterium responsible for gonorrhea.
A newborn can acquire the infection during delivery if exposed to the bacteria in the birth canal. Importantly, a pregnant person may have gonorrhea without experiencing noticeable symptoms.
What happens if a newborn develops this infection?
Gonococcal ophthalmia neonatorum can progress rapidly, sometimes appearing within the first several days after birth.
Symptoms may include:
Significant redness and swelling of the eyelids
Thick, pus-like drainage from the eyes
Irritation and inflammation of the eye
Damage to the cornea
Without prompt treatment, the infection can cause corneal ulceration, permanent vision loss, or blindness.
In severe cases, the bacteria may also cause infections elsewhere in the newborn's body.
How does erythromycin protect newborns?
Erythromycin eye ointment is applied directly to the eyes shortly after delivery. It helps prevent gonococcal eye infection before symptoms develop.
The U.S. Preventive Services Task Force (USPSTF) recommends prophylactic ocular medication for all newborns to prevent gonococcal ophthalmia neonatorum.
This preventive approach provides an additional layer of protection alongside routine prenatal screening and treatment for sexually transmitted infections.
Is erythromycin safe?
Erythromycin ophthalmic ointment has a long history of use in newborn care.
Some infants may experience temporary eye irritation or mild redness following application. The ointment can also briefly blur vision because of its consistency.
These effects are generally mild and temporary.
It is important to understand that erythromycin eye ointment specifically targets gonococcal eye infection. It does not reliably prevent every type of newborn conjunctivitis, including infections caused by chlamydia.
A small amount of antibiotic eye ointment can help prevent an uncommon but potentially sight-threatening infection.
But My Baby Is Healthy. Are These Medications Still Necessary?
This is one of the most common questions parents ask.
The answer is that preventive medicine is designed to protect children before a problem develops.
Vitamin K deficiency bleeding can occur in otherwise healthy newborns without warning. Similarly, newborn eye infections may develop after an exposure that was not recognized during pregnancy.
Neither medication is given because a baby is presumed to be sick.
Instead, they are offered because the consequences of the conditions they prevent can be serious, and effective preventive treatments are available.
What If I Have Concerns About These Medications?
As a parent, you deserve clear explanations about every medication your child receives.
It is reasonable to ask about benefits, potential side effects, and alternatives. Your pediatric healthcare team should welcome these questions and provide evidence-based information without judgment.
Vitamin K and erythromycin have different purposes, and decisions about each should be discussed individually with your newborn's healthcare team.
Giving Every Child a Healthy Start
The first hours of your baby's life are filled with important transitions. While vitamin K and erythromycin may seem like small interventions, they represent two meaningful opportunities to prevent serious complications.
At VitalStart Pediatrics, we are committed to helping families understand the science behind newborn care while respecting the important role parents play in healthcare decisions.
Whether your baby is born full-term, prematurely, or requires additional care in the neonatal intensive care unit (NICU), our goal is to help you navigate those first days with knowledge, confidence, and support.
Giving every child the VitalStart they need for a healthy life!
References
American Academy of Pediatrics Committee on Fetus and Newborn. (2022). Vitamin K and the newborn infant. Pediatrics, 149(3), e2021056036. https://doi.org/10.1542/peds.2021-056036
Centers for Disease Control and Prevention. (2025). About vitamin K deficiency bleeding. https://www.cdc.gov/vitamin-k-deficiency/about/index.html
U.S. Preventive Services Task Force. (2019). Ocular prophylaxis for gonococcal ophthalmia neonatorum: US Preventive Services Task Force reaffirmation recommendation statement. JAMA, 321(4), 394–398. https://doi.org/10.1001/jama.2018.21367
